We're unable to sign you in at this time. Please try again in a few minutes.
We were able to sign you in, but your subscription(s) could not be found. Please try again in a few minutes.
There may be a problem with your account. Please contact the AMA Service Center to resolve this issue.
Contact the AMA Service Center:
Telephone: 1 (800) 262-2350 or 1 (312) 670-7827  *   Email: subscriptions@jamanetwork.com
Error Message ......
Article |

Streptozotocin Therapy for Malignant Pheochromocytoma-Reply

Jerome M. Feldman, MD
Arch Intern Med. 1985;145(2):368. doi:10.1001/archinte.1985.00360020212042.
Text Size: A A A
Published online


—The interesting report of Gross et al certainly reinforces the fact that not all tumors of a given type will respond to an antineoplastic drug. I noted in the comments of my report that "It is also possible that it is not the difference in dose schedule but that some, but not all, patients with malignant pheochromocytomas have tumors that are sensitive to the drug (streptozotocin)."1

At the present time I cannot completely concur with Gross et al's comment "... that first line treatment, in appropriate cases, might be the recently reported radioiodinated norepinephrine analogue MIBG (meta-iodobenzylguanidine)...." In a recent report only two of five patients with malignant pheochromocytomas showed a significant clinical response to therapy with MIBG labeled with iodine 131.2 In order for a malignant pheochromocytoma to concentrate and retain MIBG 131I it is likely that the tumor will have to have an active neuronal pump


Sign in

Purchase Options

• Buy this article
• Subscribe to the journal
• Rent this article ?

First Page Preview

View Large
First page PDF preview





Also Meets CME requirements for:
Browse CME for all U.S. States
Accreditation Information
The American Medical Association is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians. The AMA designates this journal-based CME activity for a maximum of 1 AMA PRA Category 1 CreditTM per course. Physicians should claim only the credit commensurate with the extent of their participation in the activity. Physicians who complete the CME course and score at least 80% correct on the quiz are eligible for AMA PRA Category 1 CreditTM.
Note: You must get at least of the answers correct to pass this quiz.
Please click the checkbox indicating that you have read the full article in order to submit your answers.
Your answers have been saved for later.
You have not filled in all the answers to complete this quiz
The following questions were not answered:
Sorry, you have unsuccessfully completed this CME quiz with a score of
The following questions were not answered correctly:
Commitment to Change (optional):
Indicate what change(s) you will implement in your practice, if any, based on this CME course.
Your quiz results:
The filled radio buttons indicate your responses. The preferred responses are highlighted
For CME Course: A Proposed Model for Initial Assessment and Management of Acute Heart Failure Syndromes
Indicate what changes(s) you will implement in your practice, if any, based on this CME course.


Some tools below are only available to our subscribers or users with an online account.

0 Citations

Sign in

Purchase Options

• Buy this article
• Subscribe to the journal
• Rent this article ?

Related Content

Customize your page view by dragging & repositioning the boxes below.